At first glance, Novo Nordisk (NYSE:NVO) doesn't appear at all enticing. Down roughly 11% in the trailing month, NVO stock has been a victim of broader market pressure. But it's also the red ink that makes the pharmaceutical giant an enticing opportunity for options traders.
Every day, my routine involves scanning hundreds of stocks to find the most compelling opportunities to discuss. Prior to my exploration of quantitative analysis, this process involved scouring the news cycle for interesting ideas. I would then pull up price charts manually and attempt to uncover potential patterns.
